PD 407824 is an inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively). It is selective for Chk1 and WEE1 over PKC (IC50 = 3.4 μM), Cdk4 (IC50 = 3.75 μM), as well as c-Src and the PDGF and FGF receptors (IC50s = >50 μM for all), and other Cdks (IC50s = >50 μM). PD 407824 sensitizes SK-OV-3 and OVCAR-3 ovarian cancer cells, as well as cisplatin-resistant A2780cis cells, to cisplatin when used at a concentration of 0.5 μM. It also sensitizes C2C12 myoblasts to bone morphogenic protein 4 (BMP4) and, when used in combination with BMP4, inhibits myotube formation and induces myoblasts to differentiate into mature osteoblasts. PD 407824, in combination with BMP4, induces human embryonic stem cells to differentiate into cells with mesoderm or cytotrophoblast stem cell lineages.
PD-407824 has been used as a wee-1 inhibitor to study its effects on Xenopus laevis embryos. It has also been used as a checkpoint-1 (Chk-1) inhibitor to study its effects on the sensitivity of head and neck squamous carcinoma cells to gemcitabine.
PD-407824 is a Wee1/Chk1 inhibitor useful as cancer treatments.
Selective inhibitor of checkpoint kinases Chk1 and Wee1 (IC 50 values are 47 and 97 nM respectively). Displays selectivity over a range of other protein kinases; IC 50 values are 3.4, 3.75, > 5, > 50, > 50 and > 50 μ M for PKC, CDK4, other CDKs, c-Src, PDGFR and FGFR respectively.
PD-407824 is a Wee1/Chk1 inhibitor.
